Oct 16, 2025 04:06PM I-Mab plans Hong Kong IPO, rebrands as NovaBridge Biosciences

Oct 3, 2025 06:03AM Leerink Partners Starts I-Mab (IMAB) at Outperform

Sep 9, 2025 06:01AM BTIG Starts I-Mab (IMAB) at Buy

Sep 8, 2025 08:30AM I-Mab accelerates givastomig investment, names Wei Fu executive chairman

Aug 28, 2025 01:15PM I-Mab (IMAB) PT Raised to $8 at Brookline Capital Markets

Aug 21, 2025 06:36AM H.C. Wainwright Reiterates Buy Rating on I-Mab (IMAB)

Aug 20, 2025 05:02PM I-Mab Biopharma (IMAB) Misses Q2 EPS by 3c

Aug 1, 2025 08:01AM I-Mab prices $65 million offering of American depositary shares

Jul 17, 2025 07:02AM I-Mab acquires Bridge Health to strengthen givastomig IP rights

Jul 2, 2025 11:15AM I-Mab Biopharma (IMAB) Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy

Jun 30, 2025 04:01PM I-Mab (IMAB) Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research

Jun 27, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on I-Mab (IMAB)

Jun 26, 2025 06:31AM I-Mab Biopharma (IMAB) Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy

Jun 24, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on I-Mab (IMAB)

Jun 12, 2025 07:01AM I-Mab Biopharma (IMAB) Regains Nasdaq Compliance

May 28, 2025 07:34AM Lucid Capital Markets Starts I-Mab (IMAB) at Buy

Apr 4, 2025 06:41AM I-Mab (IMAB) PT Lowered to $7 at H.C. Wainwright

Mar 21, 2025 04:31PM I-Mab Biopharma (IMAB) Receives Nasdaq Non-compliance Notice

Mar 7, 2025 07:00AM I-Mab Biopharma (IMAB) Announces Accelerated Givastomig Phase 1b Study Progress

Jan 8, 2025 07:03AM I-Mab (IMAB) Announces Open Market Purchases of Company American Depositary Shares by Board Member

Nov 14, 2024 07:06AM I-Mab Biopharma (IMAB) Misses Q3 EPS by 4c

Nov 6, 2024 07:01AM I-Mab Biopharma (IMAB) Appoints Sean Fu as CEO

Sep 16, 2024 04:01PM I-Mab Biopharma (IMAB) Presents Updated Phase 1 Givastomig Data at ESMO 2024

Sep 16, 2024 07:29AM Piper Sandler Reiterates Overweight Rating on I-Mab (IMAB)

Sep 10, 2024 07:05AM I-Mab (IMAB) Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

Aug 28, 2024 07:08AM I-Mab Biopharma (IMAB) Tops Q2 EPS by 22c

Jul 15, 2024 07:31AM I-Mab Biopharma (IMAB) Appoints Wei Fu as Board Chair